BEAM earnings: real EPS beat/miss history, analyst consensus Buy, P/E -41.62. Updated 2026-07-23.
Beam Therapeutics (BEAM) Research Hub
Beam Therapeutics (BEAM) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 23.99 USD (-4.73%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -41.62, market cap 2.75B. This hub links to the full technical, earnings and options research available for BEAM.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 23.99 USD (-4.73%) |
| 52-week range | 23.95 USD – 38.26 USD |
| Trend regime | Range |
| 14-day RSI | 37.4 (Bearish) |
| Trailing P/E | -41.62 |
| Market cap | 2.75B |
| Dividend yield | 0.00% |
Available research for BEAM
Covered Call on BEAM: how it works, illustrative setup around the real 23.99 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on BEAM: how it works, illustrative setup around the real 23.99 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on BEAM: how it works, illustrative setup around the real 23.99 USD price, max profit/loss, breakeven and when to use it. Educational.
BEAM technical analysis: range, last 23.99 USD, RSI 37.4, 52w range 23.95 USD–38.26 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is BEAM in?
Beam Therapeutics (BEAM) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is BEAM in an uptrend or downtrend?
As of 2026-09-11, BEAM is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is BEAM's trailing P/E ratio?
BEAM's trailing P/E is -41.62, with a market cap of 2.75B. See the earnings research page for full valuation detail.